Abstract
Abstract: Lupus anticoagulant exerts an inhibitory effect on phospholipid-dependent coagulation tests, especially on TTP but also on PT. Depending on the type of reagents, its concentration, the technique of measurement and the heterogeneity of the antibodies, we can obtain discrepancies in the interpretation of the inhibitor. We present the case of a hemato-oncologic patient who developed a lupus inhibitor with the discrepancies in coagulation times that affected the clinical management of the patient.
Comments
Downloads
Download data is not yet available.